| Gaucher Disease, Type 1
Cerdelga vs Zavesca
Side-by-side clinical, coverage, and cost comparison for gaucher disease, type 1.Deep comparison between: Cerdelga vs Zavesca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZavesca has a higher rate of injection site reactions vs Cerdelga based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zavesca but not Cerdelga, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cerdelga
Zavesca
At A Glance
Oral
Once or twice daily
Glucosylceramide synthase inhibitor
Oral
Three times daily
Glucosylceramide synthase inhibitor
Indications
- Gaucher Disease, Type 1
- Gaucher Disease, Type 1
Dosing
Gaucher Disease, Type 1 EMs and IMs: 84 mg orally twice daily; PMs: 84 mg orally once daily; dose frequency may be reduced to once daily in EMs and IMs taking concomitant CYP2D6 or CYP3A inhibitors depending on hepatic impairment status.
Gaucher Disease, Type 1 100 mg orally three times daily at regular intervals; may reduce to 100 mg once or twice daily for tremor or diarrhea; initiate at 100 mg twice daily for mild renal impairment (CrCl 50-70 mL/min/1.73 m2), 100 mg once daily for moderate impairment (CrCl 30-50 mL/min/1.73 m2); not recommended for severe renal impairment.
Contraindications
- EMs taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor
- EMs with moderate or severe hepatic impairment
- EMs with mild hepatic impairment taking a strong or moderate CYP2D6 inhibitor
- IMs taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor
- IMs taking a strong CYP3A inhibitor
- IMs with any degree of hepatic impairment
- PMs taking a strong CYP3A inhibitor
- PMs with any degree of hepatic impairment
—
Adverse Reactions
Most common (>=10%) fatigue, headache, nausea, diarrhea, back pain, pain in extremities, upper abdominal pain
Most common (>=5%) Diarrhea, flatulence, abdominal pain, nausea, weight decrease, headache, tremor, thrombocytopenia
Serious Peripheral neuropathy
Pharmacology
Eliglustat is a specific inhibitor of glucosylceramide synthase (IC50 = 10 ng/mL) that acts as a substrate reduction therapy for Gaucher disease type 1 by reducing the production of glucosylceramide (GL-1), thereby alleviating GL-1 accumulation in the liver, spleen, bone marrow, and other target organs.
Miglustat is a competitive and reversible inhibitor of glucosylceramide synthase, reducing glycosphingolipid biosynthesis so that the residual activity of deficient glucocerebrosidase can more effectively degrade glucosylceramide substrate (substrate reduction therapy).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cerdelga
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Zavesca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Cerdelga
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Zavesca
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cerdelga
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Zavesca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CerdelgaView full Cerdelga profile
ZavescaView full Zavesca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.